Breaking News

Genmab Sells Manufacturing Facility to Baxter

March 1, 2013

Baxter acquires facility, land, and equipment in Brooklyn Park, MN

Genmab has signed an agreement with Baxter Healthcare Corp. for the sale of its non-plasma-derived antibody manufacturing facility in Brooklyn Park, MN, for $10 million. Baxter acquires the facility, land, and equipment at the site, and will offer employment to the 23 employees currently supporting the facility.
 
"We have delivered on our commitment to execute the sale of the antibody manufacturing facility in the first quarter of this year and are very pleased that Baxter acquired the facility, including the 23 employees who have maintained the facility to such a high standard," said Jan van de Winkel, Ph.D., chief executive officer of Genmab.

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks